ERBB3 blockade sensitizes HCC to regorafenib after first-line TKI resistance by inhibiting HIF1A-ABCB1 signaling

Key Points

• The research aims to explore the role of ERBB3 in limiting the effectiveness of regorafenib in HCC after TKI therapies.
• Evaluated the impact of ERBB3 blockade on regorafenib efficacy
• Compared responses in HCC models with prior TKI resistance
• Analyzed HIF1A-ABCB1 signaling pathways
• ERBB3 was identified as a significant resistance factor to regorafenib.
• Inhibition of ERBB3 increased sensitivity to regorafenib after TKI resistance.
• Disruption of HIF1A-ABCB1 signaling correlated with enhanced drug response.